Abstracts Archive - Page 366 of 2425 - ACR Meeting Abstracts

Abstract Number: 030 • 2023 Pediatric Rheumatology Symposium
International Validation of the Total Morbidity Score for Juvenile Localized Scleroderma: 2023 Update
Christina ZIgler¹, Debra Henke², Clare Pain³, Hanna Lythgoe³, Kaveh Ardalan², Kathryn Torok⁴ and Suzanne Li⁵, ¹Duke, Durham, NC, ²Duke University School of Medicine, Durham, NC, ³Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵Hackensack Meridian School of Medicine, Joseph M. Sanzari Children's Hospital, Hackensack, NJ
Background/Purpose: Juvenile localized scleroderma (jLS) is a rare condition causing inflammation and fibrosis that may impair health-related quality of life (HRQoL). Recent studies demonstrate extracutaneous…
Abstract Number: 036 • 2023 Pediatric Rheumatology Symposium
Predictive Factors of Long-lasting Remission Following Anakinra Withdrawal in Patients with Systemic Juvenile Idiopathic Arthritis After Achievement of Clinical Inactive Disease
Germana Nardini¹, Claudia Bracaglia², Denise Pires Marafon¹, Emanuela Sacco³, Arianna De Matteis¹, Ivan Caiello¹, Giusi Prencipe¹, Fabrizio De Benedetti² and Manuela Pardeo², ¹Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Roma, Italy, ²Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, ³Fondazione Casa Sollievo della Sofferenza, Pediatria, San Giovanni Rotondo, Italy
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a rare autoinflammatory disease of unknown etiology. Several uncontrolled studies showed that early treatment with anakinra is associated…
Abstract Number: 063 • 2023 Pediatric Rheumatology Symposium
JAK Inhibition in down Syndrome Associated Arthritis (DA) – Our Experience to Date with Tofacitinib in 5 Patients
Anwar Alkandari and Orla killeen, Children Health Ireland-Crumlin ( CHI ), Dublin, Ireland
Background/Purpose: Down syndrome associated arthritis (DA) is a challenging form of inflammatory arthritis that typically is more erosive and has a greater requirement for biologic…
Abstract Number: 053 • 2023 Pediatric Rheumatology Symposium
Can Children with Colchicine Resistant FMF Be Treated with on Demand Canakinumab Regimen?– a Multicenter Study
Katy shehadeh¹, Yoel Levinsky², rotem tal³, Neta Hana Aviran³, Yonatan Butbul Aviel⁴, Irit Tirosh⁵, Shelly Kagan⁶, Tarek Zoabi³, Shiri Spielman⁷, Adi Miller-Barmak⁴, Rotem Semo Oz⁸, Liora Harel⁹, Gabriel Chodick¹⁰ and Gil Amarilyo⁶, ¹Tel Aviv University, Tel Aviv, Israel, ²Schneider Children's Medical Center of Israel, Tel Aviv University, Petach Tikva, Israel, ³Schneider Children's Medical Center of Israel, Petach Tikva, Israel, ⁴Rambam Medical center, Haifa, Israel, ⁵Sheba Medical Center, Savyon, Israel, ⁶Schneider Children's Medical Center of Israel, Petach Tikva, Israel, ⁷Sheba Tel-HaShomer Medical Center, Givataim, Israel, ⁸Sheba medical center, Herzelyia, Israel, ⁹Scheiders Children Medical Center of Israel, Petah-Tiqva, Israel, ¹⁰Maccabitech institute for research and innovation, Maccabi healthcare services, Tel Aviv, Israel
Background/Purpose: Familial Mediterranean fever (FMF) is the most common autoinflammatory disease. Without therapy, it may lead to the development of secondary amyloidosis. Treatment with colchicine…
Abstract Number: 045 • 2023 Pediatric Rheumatology Symposium
Patient Reported Outcomes in Pediatric Vasculitis
Clare Peckenpaugh¹, Aimee Hersh², CJ Inman¹, Sara Stern¹, Erin Treemarcki², Peter Merkel³ and Karen James¹, ¹University of Utah Department of Pediatrics, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT, ³University of Pennsylvania, Philidelphia, PA
Background/Purpose: Vasculitis is a group of multisystem, often relapsing diseases that can affect patients through disease activity, damage, and treatment toxicity. Vasculitis in adults often…
Abstract Number: 018 • 2023 Pediatric Rheumatology Symposium
Using the Electronic Health Record to Identify Subjects with Rheumatic Disease
Alysha Taxter¹, Matthew Basiaga², Rajdeep Pooni³, Caitlan Pinotti⁴, Lisa Buckley⁵ and CARRA Registry Investigators⁶, ¹Nationwide Children's Hospital, Columbus, OH, ²Mayo Clinic, Rochester, MN, ³Stanford University, Palo Alto, CA, ⁴Duke, Durham, NC, ⁵Vanderbilt University Medical Center, Nashville, TN, ⁶CARRA, Washington, DC
Background/Purpose: Research teams spend hours manually searching the electronic health records (EHRs) to identify potential candidates eligible for recruitment to the Childhood Arthritis and Rheumatology…
Abstract Number: 055 • 2023 Pediatric Rheumatology Symposium
COVID-19 Vaccination in Children with Rheumatic Diseases: Results of a CARRA-wide Survey
Beth Rutstein¹, Merav Heshin Bekenstein², Maria Schletzbaum³, Nora Singer⁴, Rebecca Sadun⁵, Melanie Kohlheim⁶, Vincent Del Gaizo⁷, Kelly Wise⁸, Melica Nikahd⁹, Guy Brock⁹, Monica Ardura⁸, Vidya Sivaraman¹⁰ and For the CARRA Investigators¹¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Tel Aviv Medical Center, Tel Aviv, Israel, ³Medical College of Wisconsin, Milwaukee, WI, ⁴Metro Health, Cleveland, OH, ⁵Duke University, Durham, NC, ⁶None, Columbus, OH, ⁷CARRA, Washington, DC, ⁸Nationwide Children's Hospital, Columbus, OH, ⁹The Ohio State University, Columbus, OH, ¹⁰Nationwide Children's Hospital/ The Ohio State University, Columbus, OH, ¹¹Duke University Medical Center, Durham, NC
Background/Purpose: Children receiving immunosuppressive therapies (IST) have a higher risk of hospitalization from COVID-19. COVID-19 vaccines significantly reduce the likelihood of severe disease or death.…
Abstract Number: 065 • 2023 Pediatric Rheumatology Symposium
Relationship Between Arthritis and Uveitis Disease Activity in Children with JIA
Meghana Karumuri¹, Megan Quinlan-Waters², Alexandra Duell², Kelly Rogers², Sheila Angeles-Han³ and Patricia Vega-Fernandez², ¹Michigan State University, Novi, MI, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Uncontrolled uveitis can lead to visual complications in 50% of children with JIA associated uveitis (JIA-U). While arthritis and uveitis are not considered to…
Abstract Number: 060 • 2023 Pediatric Rheumatology Symposium
Are the Levels of Cytokines Good Biomarkers for Smoldering Disease Activity in Childhood-Takayasu Arteritis?
Gleice Clemente¹, Maria Teresa Terreri², Bruno Gualano³, Clovis Silva⁴ and Alexandre Wagner De Souza¹, ¹Universidade Federal de São Paulo, São Paulo, Brazil, ²UNIFESP, São Paulo, Brazil, ³Universidade de São Paulo, São Paulo, ⁴Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Biomarkers for disease activity in adult Takayasu arteritis (TA) have been studied exhaustively, but there are inconsistencies among the studies (1). Childhood-TA (c-TA) differs…
Abstract Number: 057 • 2023 Pediatric Rheumatology Symposium
A “High-Risk” Depression/Fatigue Profile May Be Associated with Stronger Response to a Psychological Treatment for Childhood-Onset Systemic Lupus Erythematosus (cSLE)
Elizabeth Ross¹, khalid abulaban², Elizabeth Kessler², Andrea Knight³ and Natoshia Cunningham⁴, ¹Michigan State University College of Human Medicine, Grand Rapids, MI, ²Helen DeVos Children's Hospital, Grand Rapids, MI, ³The Hospital for Sick Children, Toronto, ON, Canada, ⁴Michigan State University, Grand Rapids, MI
Background/Purpose: Children with childhood-onset systemic lupus erythematosus (cSLE) experience more severe disease than their adult counterparts, in addition to high rates of clinical depressive symptoms…
Abstract Number: 068 • 2023 Pediatric Rheumatology Symposium
Outcomes of Children with Uveitis Associated with Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy (ADNIV)
Ilaria Maccora¹, Arjun Sood², Grant Schulert³, Megan Quilan-Water³, Alexandra Duell³, Jennifer Huggins³, Tiffany Nguyen², Cameron Sapp², Sumit Sharma⁴, Srivastaval Sunil⁴ and Sheila Angeles-Han⁵, ¹IRCCS Meyer Children’s Hospital, Rheumatology Unit, Florence, Italy, ²Cincinnati Eye Institute, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Cole Eye Institute, Cleveland Clinic, Cleveland, OH, ⁵Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Pediatric uveitis is commonly associated with rheumatic disease and can lead to sight-threatening complications if not properly treated. Systemic immunomodulatory therapy has dramatically changed…
Abstract Number: 080 • 2023 Pediatric Rheumatology Symposium
Analysis of Proteasomal Activity – a Potential Diagnostic Tool for Proteasome-associated Autoinflammatory Syndromes (PRAAS)
Yoel Levinsky¹, Oded Scheuerman², Rotem Tal³, Gil Amarilyo³ and Liora Harel³, ¹Schneider Children's Medical Center of Israel, Tel Aviv University, Petach Tikva, Israel, ²Pediatric B department, Schneider children's medical center of Israel, Petach Tikva, Israel, ³Pediatric rheumatology clinic, Schneider children's medical center of Israel, Petach Tikva, Israel
Background/Purpose: Interferonopathies are a recently recognized group of genetic syndromes associated with uncontrolled activation of interferon. PRAAS (proteasome-associated autoinflammatory syndromes) is an interferonopathy caused by…
Abstract Number: 081 • 2023 Pediatric Rheumatology Symposium
Predicting Extension in Juvenile Idiopathic Arthritis
Megan Simonds¹, Kathleen Sullivan² and AnneMarie Brescia¹, ¹Nemours Children's Health, Wilmington, DE, ²Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease of childhood and carries a risk of permanent joint damage and disability [1]. In…
Abstract Number: 074 • 2023 Pediatric Rheumatology Symposium
Clinical Characteristics of Juvenile Systemic Sclerosis in Korea: A 30-year Single Center Study
Jieun Jeong¹, Minji Kim¹, Jiwon Jung², Seon Hee Lim³ and Seong Heon Kim¹, ¹Department of Pediatrics, Seoul National University Children’s Hospital, Seoul, Republic of Korea, ²Department of Pediatrics, Asan Medical Center Children’s Hospital, University of Ulsan College of Medicine, Seoul, Republic of Korea, ³Department of Pediatrics, Pusan National University Children’s Hospital, Yangsan, Republic of Korea
Background/Purpose: Juvenile systemic sclerosis (jSSc) is a rare autoimmune, chronic, multisystem, connective tissue disease characterized by progressive tissue fibrosis of the skin and internal organs.…
Abstract Number: 039 • 2023 Pediatric Rheumatology Symposium
Towards the Definition of Cutoff Values for Disease Activity States in Systemic JIA Using the Systemic Juvenile Arthritis Disease Activity Score
Ana Isabel Rebollo-Giménez¹, Yulia Vyzhga², Luca Carlini³, Silvia Rosina⁴, Elisa Patrone¹, Maria Katsikas⁵, Claudia Magalhaes⁶, Dalia El-Ghoneimy⁷, Yasser El Miedany⁸, Raju Khubchandani⁹, Priyankar Pal¹⁰, Gabriele Simonini¹¹, Giovanni Filocamo¹², Maurizio Gattinara¹³, Fabrizio De Benedetti¹⁴, Davide Montin¹⁵, Adele Civino¹⁶, Muatasem Alsuweiti¹⁷, Valda Stanevicha¹⁸, Vyacheslav Chasnyk¹⁹, Ekaterina Alexeeva²⁰, Sulaiman M Al-Mayouf²¹, Soamarat Vilaiyuk²² and Angelo Ravelli²³, ¹IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattie Infiammatorie, Genova, Italy, ²IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattia Infiammatorie, Genova, Italy, ³IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattie Autoinfiammatorie, Genova, Italy, ⁴IRCCS Istituto Giannina Gaslini, Genova, Italy, ⁵Hospital de Pediatria Juan P. Garrahan, Department of Immunology/Rheumatology, Buenos Aires, Argentina, ⁶São Paulo State University, Pediatric Rheumatology Division, Botucatu, Brazil, ⁷Children's Hospital, Ain Shams University, Pediatric Allergy, Immunology and Rheumatology Unit, Cairo, Egypt, ⁸Ain Shams University, Department of Rheumatology and Rehabilitation, Cairo, Egypt, ⁹Jaslok Hospital and Research Centre, Department of Paediatrics, Mumbai, India, ¹⁰Institute of Child Health, Pediatric medicine, Kolkata, India, Kolkata, India, ¹¹IRCCS Meyer Children’s Hospital, Rheumatology Unit, Florence, Italy, ¹²Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, Pediatric Rheumatology, Milano, Italy, ¹³Istituto Gaetano Pini, Rheumatology Unit, Milano, Italy,, Genova, ¹⁴Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, ¹⁵Regina Margherita Children Hospital, Immunology and Rheumatology Unit, Turin, Italy, ¹⁶Ospedale Vito Fazzi, Paediatric Immunology/Rheumatology Service, Lecce, Italy, ¹⁷King Hussein Medical Center, Department of Pediatrics - Pediatric Allergy, Immunology & Rheumatology Clinic, Amman, Jordan, ¹⁸University Children Hospital, Department of Pediatrics, Riga, Latvia, ¹⁹Saint-Petersburg State Pediatric Medical University, Department of Hospital Pediatrics, St. Petersburg, Russia, ²⁰Federal State Autonomous Institution “National Medical Research Center of Children's Health”, Ministry of Health of the Russian Federation, Moscow, Russia, ²¹King Faisal Specialist Hospital & Research Center, Alfaisal University, Department of Pediatric Rheumatology, Riyadh, Saudi Arabia, ²²Mahidol University Faculty of Medicine, Ramathibodi Hospital Department of Pediatrics, Bangkok, Thailand, ²³IRRCS Istituto Giannina Gaslini and Università degli Studi di Genova, Genova, Italy
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) accounts up to 15% of all patients with JIA and is distinctfrom the other disease categories due to the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].